RT Journal Article
SR Electronic
T1 BNT162b2 effectiveness against Delta & Omicron variants in teens by dosing interval and duration
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.27.22276790
DO 10.1101/2022.06.27.22276790
A1 Iulia G. Ionescu
A1 Danuta M. Skowronski
A1 Chantal Sauvageau
A1 Erica Chuang
A1 Manale Ouakki
A1 Shinhye Kim
A1 Gaston De Serres
YR 2022
UL http://medrxiv.org/content/early/2022/07/13/2022.06.27.22276790.abstract
AB Background and Objectives Two- and three-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccine effectiveness (VE) against SARS-CoV-2 infection, including Delta and Omicron variants, was assessed among adolescents in two Canadian provinces where first and second doses were spaced longer than the manufacturer-specified 3-week interval.Methods Test-negative design estimated VE against laboratory-confirmed SARS-CoV-2 infection among 12-17-year-olds in Quebec and British Columbia, Canada between September 5, 2021 (epi-week 36), and April 30, 2022 (epi-week 17). Delta-dominant and Omicron-dominant periods spanned epi-weeks 36-47 and 51-17, respectively. VE was assessed from 14 days and explored by interval between first and second doses, time since second dose, and with administration of a third dose.Results Median first-second dosing-interval was ∼8 weeks and second-third dosing-interval was ∼29-31 weeks. Median follow-up post-second dose was ∼10-11 weeks for Delta-dominant and ∼21-22 weeks for Omicron-dominant periods, and ∼2-7 weeks post-third dose. VE against Delta was ≥90% to at least the 5th month post-second dose. VE against Omicron declined from ∼65-75% at 2-3 weeks to ≤50% by the 3rd month post-vaccination, restored to ∼65% shortly following a third dose. VE exceeded 90% against Delta regardless of dosing-interval but appeared improved against Omicron with ≥8 weeks between first and second doses.Conclusion In adolescents, two BNT162b2 doses provided strong and sustained protection against Delta but reduced and rapidly-waning VE against Omicron. Longer interval between first and second doses and a third dose improved Omicron protection. Updated vaccine antigens, increased doses and/or dosing-intervals may be needed to improve adolescent VE against immunological-escape variants.Competing Interest StatementGDS received a grant from Pfizer for an unrelated topic. DMS has received grants for unrelated work paid to her institute from the Public Health Agency of Canada, the Michael Smith Foundation for Health Research and the Canadian Institutes of Health Research. None for other authors.Funding StatementThe Ministère de la santé et des services sociaux du Québec and the BCCDC Foundation for Public Health provided funding support but had no role in the design, results, interpretation or decision to submit.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data linkages and analyses were authorized by the Provincial Health Officer (BC) and National Director of Public Health (Quebec) under respective provincial public health legislation without requirement for research ethics board review. The University of British Columbia Clinical Research Ethics Board waived ethical approval for this work in BC; the Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Ethics Board provided ethical approval for this work in QuebecI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSharing of de-identified data that underpin the vaccine effectiveness results reported in this article will be considered upon request with appropriate review and aggregation as required to comply with respective provincial/national privacy and confidentiality legislation and through secure file transfer protocols. Information regarding submitting proposals and accessing data may be obtained through the corresponding authors.AORadjusted odds ratioCIconfidence intervalCOVID-19coronavirus disease 2019mRNAmessenger RNANAATnucleic acid amplification testNACICanadian National Advisory Committee on ImmunizationSARS-CoV-2severe acute respiratory syndrome coronavirus 2TNDtest-negative designVEvaccine effectivenessVOCvariant of concern